Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15116482 | 0.90 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL12928711 | 0.90 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL15116846 | 0.81 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL15116859 | 0.81 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL27777472 | 0.77 | DGAT1 (0.54) | DGAT1 | |
| SCHEMBL12348845 | 0.74 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL18559 | 0.74 | DGAT1 (0.52) | DGAT1 | |
| SCHEMBL22572567 | 0.74 | DGAT1 (0.52) | DGAT1 | |
| SCHEMBL8907034 | 0.74 | DGAT1 (0.46) | DGAT1 | |
| Hydrochloric Acid SCHEMBL23094114 | 0.72 | DGAT1 (0.50) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110872230-B | Preparation method of 1- (trifluoromethyl) cyclopropane-1-carboxylic acid compound and intermediate thereof | 浙江九洲药业股份有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-110872230-A | Preparation method and intermediate of 1- (trifluoromethyl) cyclopropane-1-carboxylic acid compound | 浙江九洲药业股份有限公司 | 2020-03-10 | — | — | CN | claimed |
| EP-4634159-A1 | SULFOXIMINES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-10-22 | — | — | EP | disclosed |
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | GRUENENTHAL GMBH (DE) | 2024-08-01 | — | — | US | disclosed |
| EP-4397309-A2 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024126648-A1 | SULFOXIMINES AS INHIBITORS OF NaV1.8 | Grünenthal GmbH (DE) | 2024-06-20 | — | — | WO | disclosed |
| CN-118176179-A | Novel spiro compounds | 田边三菱制药株式会社 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024112830-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026486-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024010963-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2024-01-11 | — | — | WO | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| WO-2008057857-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20080009470-A1 | Acremonic Acid Derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2008-01-10 | — | — | US | disclosed |
| US-20080009470-A1 | Acremonic Acid Derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009470-A1 | Acremonic Acid Derivatives | UGT1A6, ACR, CYP2B6 | DGAT1 1894/4885SMN1; SMN2 2618/4885 |
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NR0B1, NFKB2 | DGAT1 2395/4885SMN1; SMN2 4149/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | DGAT1 811/4885SMN1; SMN2 4352/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | DGAT1 811/4885SMN1; SMN2 4352/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | DGAT1 1118/4885SMN1; SMN2 3515/4885 |
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | SCN8A, SCN10A, SCN7A | DGAT1 3043/4885SMN1; SMN2 317/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | DGAT1 811/4885SMN1; SMN2 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.